Clinical Trials Logo

Nonsmall Cell Lung Cancer clinical trials

View clinical trials related to Nonsmall Cell Lung Cancer.

Filter by:

NCT ID: NCT03002844 Not yet recruiting - Clinical trials for Nonsmall Cell Lung Cancer

EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Start date: December 2016
Phase: Phase 2
Study type: Interventional

BIM deletion polymorphism might be associated with a poor clinical response to EGFR-TKIs in patients who had NSCLC with EGFR mutations. In the study, the investigators want to use EGFR-TKI with/without chemotherapy as first line treatment in stage IIIB/IV NSCLC patients with both EGFR mutation and BIM deletion polymorphism.

NCT ID: NCT02994576 Completed - Clinical trials for Nonsmall Cell Lung Cancer

Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer

PRINCEPS
Start date: December 12, 2016
Phase: Phase 2
Study type: Interventional

Based on the efficacy of immunotherapies in advanced disease with a reasonable safety profile/tolerability we could hypothesize that, immunotherapy should work best in the situation of minimal residual disease, Two clinical trials are ongoing to test the role of immunotherapeutic agents in the adjuvant setting: PEARLS trial, a randomized phase III trial with anti-PD1 monoclonal antibody pembrolizumab (MK-3475 or pembrolizumab) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy, and the second randomized phase III trial (NCT02273375) will evaluate the efficacy of an anti-PD-L1 (MEDI 4736) for a maximum of 12 months versus placebo as adjuvant therapy in completed resected stage IB-IIIA NSCLC and completed standard ACT. The role of immunotherapeutic approaches for NSCLC in the neoadjuvant setting is currently unknown. However, based on the survival efficacy of immunotherapeutic strategies in advanced NSCLC where the tumor has not been removed which could produce higher immunogenicity and based on the efficacy of neoadjuvant treatments in NSCLC, we propose to test the safety and efficacy of atezolizumab as neoadjuvant therapy in subjects diagnosed with stage I, II, or IIIA (non N2) NSCLC and who are deemed suitable for surgical resection. Clinical staging of NSCLC is based on computed tomography (CT) of the chest and upper abdomen, brain CT or magnetic resonance imaging and 18F-FDG PETscan to rule out metastatic disease and assess the potential for curative-intent resection. Adjuvant chemotherapy will be performed according the standard clinical guidelines.

NCT ID: NCT02988141 Not yet recruiting - Clinical trials for Nonsmall Cell Lung Cancer

EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

PRECENT
Start date: March 2017
Phase: N/A
Study type: Observational

A Prospective Multi-center Study to Investigate the EGFR-TKI Resistance Profile in Chinese Patients with Advanced EGFRm+ NSCLC

NCT ID: NCT02981108 Active, not recruiting - Clinical trials for Nonsmall Cell Lung Cancer

A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC

Start date: May 8, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, multicenter study of HS-10296 with dose escalation, dose expansion and extension cohorts in locally advanced or metastatic non-small-cell lung cancer (NSCLC) patients who have progressed following prior therapy with an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor (TKI) agent. The study is designed to evaluate safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of once-daily and orally (PO) administered HS-10296. The overall study design is shown in the flow chart below, which consists of 3 phases: dose escalation, dose expansion and extension cohort.

NCT ID: NCT02980536 Active, not recruiting - Adenocarcinoma Clinical Trials

cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China

Start date: November 2016
Phase:
Study type: Observational

The purpose of this study is to evaluate the mutation pattern of epidermal growth factor receptor (EGFR) and other TKI targeted gene during TKI treatment of advanced NSCLC patient with liquid biopsy.

NCT ID: NCT02974933 Recruiting - Clinical trials for Nonsmall Cell Lung Cancer

Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer

Start date: November 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of apatinib mesylate combined with pemetrexed alone in advanced non-small cell lung cancer patients in the second or second line of treatment of progression-free survival

NCT ID: NCT02973789 Active, not recruiting - NSCLC Clinical Trials

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

Start date: December 2016
Phase: Phase 3
Study type: Interventional

The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-200T device, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

NCT ID: NCT02972333 Not yet recruiting - Brain Metastases Clinical Trials

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Start date: December 2016
Phase: Phase 3
Study type: Interventional

The study aims to investigate the efficacy and safety of AZD9291 in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI.

NCT ID: NCT02972216 Completed - Clinical trials for Squamous Cell Carcinoma of the Head and Neck

Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy

Start date: November 2014
Phase: Phase 4
Study type: Observational

A Post-marketing Surveillance Study to Evaluate the Effectiveness and Safety of Docetaxel-Based Chemotherapy

NCT ID: NCT02967133 Terminated - Clinical trials for Nonsmall Cell Lung Cancer

A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer

Start date: December 2016
Phase: Phase 2
Study type: Interventional

The optimal prioritization of second-line chemotherapy and immune therapy based on demographic or biomarker data is an area of ongoing investigation. The hypothesis of this study is that there may be an additive or synergistic antitumor effect of combined chemotherapy and nivolumab in the second-line treatment of NSCLC as an important concept to test in a clinical trial. Previously treated NSCLC remains a setting of unmet clinical need despite recent clinical research progress. Early progression for a subset of NSCLC patients receiving nivolumab is a specific area of clinical need.